Teva to buy Auspex in all-cash deal

Drugmaker Teva Pharmaceuticals said it would buy Auspex for $101 per share in cash, or $3.5 billion in equity value.

Teva said the deal, done at a 42 percent premium, would add a portfolio of drugs for the treatment of central nervous system disorders.

Auspex shares closed Friday at $70.91 and had not traded premarket Monday. Teva shares rose 1.5 percent in premarket trading.